Search This Blog

Friday, August 21, 2009

TOPICAL AVASTIN MAY DECREASE PKP GRAFT REJECTION

Eur J Ophthalmol 2009; 19: 870 - 872

Short-term topical bevacizumab (Avastin) therapy may potentially offer a safer and more effective alternative in treating graft rejection after penetrating keratoplasty (corneal transplant).

No comments:

Post a Comment

Leave a Comment or Question: